Testing for BRAF mutation is beneficial in judicious selection of patients for targeted therapy[8,9] and also a cost effective approach in the HNPCC (Hereditary Non-polyposis Colorectal Cancer) workup; presence of BRAF mutation with absence of MLH1 protein is indicative of sporadic CRC[14,15]. This evidence concerns the gene BRAF and hereditary nonpolyposis colon cancer.